Customer Education

Hepatocyte Webinar

 

 What Does it Cover?

The liver is a key organ for drug metabolism and disposition, the focus of a number of novel therapeutic programs, and a target for a number of toxic chemicals and drugs. Thus, liver tissue and its associated cells are in high demand for both in vitro and in vivo applications, as well as predictive modeling for the assessment of drug safety. Species differences in liver biology and response to xenobiotics, along with programs aimed at reducing the use of animals in drug testing, are pushing the research community to rely more heavily on the use of human cell-based models. In recent years, there is a growing acknowledgment that the main drug-metabolizing cell type in the liver (the hepatocyte) should not be used in isolation to ask important preclinical questions, but is best combined with additional liver cell types and other parameters, such as fluid flow, to more accurately model complex in vivo outcomes.  Regardless of the specific application, most tissue engineering and regenerative medicine platforms and strategies involve the use of living human cells and/or their derivatives. However, the interpretation of outcomes is often contextual in nature and relies heavily on the quality and condition of the cellular materials. Responses of primary cells in vitro are influenced by the genetic and epigenetic background of the donor of origin. The variation in outcomes is dictated in part by the inherent quality and heterogeneity of human donor starting materials, which can be compounded further by technical variations in tissue recovery, cell isolation methods, and characterization assays.  These important factors impact lot to lot reproducibility and ultimately create significant challenges in the development of reliable application-specific standards for cellular materials.  This presentation will focus on the current trends in hepatic culture technologies and considerations for how they are impacted by the quality and performance of the cell materials used. The current state-of-the-art in procurement, production and characterization of primary hepatocytes for in vitro research applications will be reviewed, and measures for improving the validation and qualification of hepatic cells for specific applications also will be proposed.
 

 What Will You Learn?

  • Current challenges with the use of primary hepatocytes for basic research applications
  • The state of the art in tissue procurement and hepatocyte isolation techniques; Improved measures for the characterization and validation of primary hepatocytes lots for specific research applications
  • Efforts towards creating universal standards and quality metrics for the use of human tissues and cells for basic research applications

 Who Should Attend?

  • Academic researchers
  • Pharma researchers
  • ADME scientists
  • DMPK scientists
  • Toxicology scientists
  • Drug discovery scientists

 

Speaker Bio
Edward L. LeCluyse, Ph.D.
Principal Scientist
LifeNet Health, Institute of Regenerative Medicine, LifeSciences Division
Edward LeCluyse is a Principal Scientist in the LifeSciences Division, Institute of Regenerative Medicine at LifeNet Health, Research Triangle Park, NC, and is a participating faculty member of the Curriculum in Toxicology at The University of North Carolina at Chapel Hill (UNC-CH).  Dr. LeCluyse received his Ph.D. in Biochemistry at the University of Kansas and did his post-doctoral training at the University of Kansas Medical School.  He has over 25 years of experience in the field of in vitro pharmacology and toxicology, has held industry positions at Merck, CellzDirect, and Invitrogen, and academic positions at The Hamner Institutes for Health Sciences and UNC’s Eshelman School of Pharmacy.  More recently, his research has focused on the isolation of primary liver cells from both normal and diseased tissues and the development of novel in vitro human hepatic model systems to study mechanisms of liver disease.  Dr. LeCluyse is the author of over 100 publications, book chapters, and review articles, and has presented numerous lectures and workshops on topics such as enzyme-induced drug interactions, mechanisms of DILI, and in vitro hepatic culture model systems.